Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications

Noémi Zsíros, Péter Koncsos, Hajnalka Lorincz, I. Seres, Mónika Katkó, Anita Szentpéteri, Viktória E. Varga, Péter Fülöp, G. Paragh, M. Harangi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: Myeloperoxidase (MPO), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) were shown to contribute to atherogenesis, while human paraoxonase-1 (PON1) protects against oxidative stress. Although several studies investigated these biomarkers, their associations have not been completely clarified yet. We aimed to investigate these parameters in overweight hyperlipidemic, lipid-lowering therapy-naive patients (n = 167) with and without vascular complications. Design and methods: MPO, MMP-9 and TIMP-1 levels were measured by ELISA. PON1 activities were detected spectrophotometrically. PON1 phenotype was calculated by using a dual substrate method. Results: Patients with vascular complications (VC) had significantly higher MPO and TIMP-1 levels compared to those without (patients with no vascular complications; NVC) (728 (367.25-1177.90) mg/ml vs. 315.9 (176.05-687.40) mg/ml; p.

Original languageEnglish
JournalClinical Biochemistry
DOIs
Publication statusAccepted/In press - Dec 30 2015

Fingerprint

Aryldialkylphosphatase
Matrix Metalloproteinase 1
Tissue Inhibitor of Metalloproteinase-1
Peroxidase
Blood Vessels
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinase 9
Tissue
Oxidative stress
Biomarkers
Atherosclerosis
Oxidative Stress
Enzyme-Linked Immunosorbent Assay
Phenotype
Lipids
Substrates
arylesterase
Therapeutics

Keywords

  • Hyperlipidemia
  • MMP-9
  • Myeloperoxidase
  • Obesity
  • Paraoxonase-1
  • TIMP-1

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications. / Zsíros, Noémi; Koncsos, Péter; Lorincz, Hajnalka; Seres, I.; Katkó, Mónika; Szentpéteri, Anita; Varga, Viktória E.; Fülöp, Péter; Paragh, G.; Harangi, M.

In: Clinical Biochemistry, 30.12.2015.

Research output: Contribution to journalArticle

Zsíros, Noémi ; Koncsos, Péter ; Lorincz, Hajnalka ; Seres, I. ; Katkó, Mónika ; Szentpéteri, Anita ; Varga, Viktória E. ; Fülöp, Péter ; Paragh, G. ; Harangi, M. / Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications. In: Clinical Biochemistry. 2015.
@article{fda4508ae9c64da6a02beef6d62e30c9,
title = "Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications",
abstract = "Objectives: Myeloperoxidase (MPO), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) were shown to contribute to atherogenesis, while human paraoxonase-1 (PON1) protects against oxidative stress. Although several studies investigated these biomarkers, their associations have not been completely clarified yet. We aimed to investigate these parameters in overweight hyperlipidemic, lipid-lowering therapy-naive patients (n = 167) with and without vascular complications. Design and methods: MPO, MMP-9 and TIMP-1 levels were measured by ELISA. PON1 activities were detected spectrophotometrically. PON1 phenotype was calculated by using a dual substrate method. Results: Patients with vascular complications (VC) had significantly higher MPO and TIMP-1 levels compared to those without (patients with no vascular complications; NVC) (728 (367.25-1177.90) mg/ml vs. 315.9 (176.05-687.40) mg/ml; p.",
keywords = "Hyperlipidemia, MMP-9, Myeloperoxidase, Obesity, Paraoxonase-1, TIMP-1",
author = "No{\'e}mi Zs{\'i}ros and P{\'e}ter Koncsos and Hajnalka Lorincz and I. Seres and M{\'o}nika Katk{\'o} and Anita Szentp{\'e}teri and Varga, {Vikt{\'o}ria E.} and P{\'e}ter F{\"u}l{\"o}p and G. Paragh and M. Harangi",
year = "2015",
month = "12",
day = "30",
doi = "10.1016/j.clinbiochem.2016.03.011",
language = "English",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications

AU - Zsíros, Noémi

AU - Koncsos, Péter

AU - Lorincz, Hajnalka

AU - Seres, I.

AU - Katkó, Mónika

AU - Szentpéteri, Anita

AU - Varga, Viktória E.

AU - Fülöp, Péter

AU - Paragh, G.

AU - Harangi, M.

PY - 2015/12/30

Y1 - 2015/12/30

N2 - Objectives: Myeloperoxidase (MPO), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) were shown to contribute to atherogenesis, while human paraoxonase-1 (PON1) protects against oxidative stress. Although several studies investigated these biomarkers, their associations have not been completely clarified yet. We aimed to investigate these parameters in overweight hyperlipidemic, lipid-lowering therapy-naive patients (n = 167) with and without vascular complications. Design and methods: MPO, MMP-9 and TIMP-1 levels were measured by ELISA. PON1 activities were detected spectrophotometrically. PON1 phenotype was calculated by using a dual substrate method. Results: Patients with vascular complications (VC) had significantly higher MPO and TIMP-1 levels compared to those without (patients with no vascular complications; NVC) (728 (367.25-1177.90) mg/ml vs. 315.9 (176.05-687.40) mg/ml; p.

AB - Objectives: Myeloperoxidase (MPO), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) were shown to contribute to atherogenesis, while human paraoxonase-1 (PON1) protects against oxidative stress. Although several studies investigated these biomarkers, their associations have not been completely clarified yet. We aimed to investigate these parameters in overweight hyperlipidemic, lipid-lowering therapy-naive patients (n = 167) with and without vascular complications. Design and methods: MPO, MMP-9 and TIMP-1 levels were measured by ELISA. PON1 activities were detected spectrophotometrically. PON1 phenotype was calculated by using a dual substrate method. Results: Patients with vascular complications (VC) had significantly higher MPO and TIMP-1 levels compared to those without (patients with no vascular complications; NVC) (728 (367.25-1177.90) mg/ml vs. 315.9 (176.05-687.40) mg/ml; p.

KW - Hyperlipidemia

KW - MMP-9

KW - Myeloperoxidase

KW - Obesity

KW - Paraoxonase-1

KW - TIMP-1

UR - http://www.scopus.com/inward/record.url?scp=84965151887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965151887&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2016.03.011

DO - 10.1016/j.clinbiochem.2016.03.011

M3 - Article

C2 - 27129797

AN - SCOPUS:84965151887

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

ER -